<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203982</url>
  </required_header>
  <id_info>
    <org_study_id>VF-20060060</org_study_id>
    <nct_id>NCT01203982</nct_id>
  </id_info>
  <brief_title>Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT)</brief_title>
  <official_title>Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima Media Thickness and Its Relation to Plaque Components of the Coronary Arteries in Patients With ST-Segment Elevation Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to measure the effect of moderate and intensive lipid-lowering
      treatment with rosuvastatin on the carotid intima-media thickness (CIMT) as a surrogate
      marker of cardiovascular risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study was to measure the effect of moderate (5mg) and intensive (40mg)
      lipid-lowering treatment with rosuvastatin on the carotid intima-media thickness as a
      surrogate marker of cardiovascular risk and to obtain whether CIMT correlated with the plaque
      components in coronary arteries evaluated with Intravascular Ultrasound Virtual Histology
      (IVUS-VH).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in mean CIMT</measure>
    <time_frame>baseline, 6month, 12 month</time_frame>
    <description>Average of the far wall of common and bulbus carotid artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in max CIMT</measure>
    <time_frame>baseline, 6month, 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in mean common CIMT</measure>
    <time_frame>baaseline, 6month 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in max common CIMT</measure>
    <time_frame>baseline, 6month 12month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in mean bulbus CIMT</measure>
    <time_frame>Baseline, 6month 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in max bulbus CIMT</measure>
    <time_frame>baseline, 6month 12month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in lipid values</measure>
    <time_frame>baseline, 6month 12month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between CIMT measurements and lipid values</measure>
    <time_frame>Baseline, 6month 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between CIMT measurements and plaque components evaluated by IVUS-VH</measure>
    <time_frame>Baseline, 6month 12month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>ST-segment Elevation Myocardial Infarction</condition>
  <condition>Subclinical Carotid Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 5mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 40mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 5mg/day for one year</description>
    <arm_group_label>Rosuvastatin 5mg</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 40mg/day for one year</description>
    <arm_group_label>Rosuvastatin 40mg</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. STEMI,

          2. no prior treatment with statins and

          3. a non significant lesion in one of the two non-culprit coronary arteries. -

        Exclusion Criteria:

          1. age below 18 or above 81 years,

          2. unconscious patients,

          3. serum creatinine &gt; 176Î¼mol/L,

          4. total-cholesterol &gt; 7.0 mmol/l,

          5. hypothyroidism ((TSH &gt; 1.5 x ULN (upper limit of normal)),

          6. current liver disease (ALAT &gt; 2 x ULN),

          7. unexplained creatine kinase &gt; 3 x ULN,

          8. alcohol or drug abuse within the last five years,

          9. prior myopathy or serious hypersensitivity reaction caused by statins,

         10. women with childbearing potential who were not using chemical or mechanical
             contraception,

         11. pregnant or breastfeeding women,

         12. history of malignancy unless a disease-free period of more than five years was
             present,

         13. patients with abnormal lung function test (LFT),

         14. participation in another investigational drug study less than four weeks before
             enrolment in the present study,

         15. treatment with cyclosporine or fibrates. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Cardiology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Fuenen</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2010</study_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rasmus Egede</name_title>
    <organization>Odense University Hospital</organization>
  </responsible_party>
  <keyword>CIMT</keyword>
  <keyword>IVUS-VH</keyword>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

